Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Metastatic Castrate Resistant Prostate Cancer 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × tasquinimod × Clear all
NCT02057666 2021-04-23

TasQ003

Ipsen

Phase 3 Terminated
146 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡